These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 7693450)
1. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. Yamaguchi S; Donevan SD; Rogawski MA Epilepsy Res; 1993 Jul; 15(3):179-84. PubMed ID: 7693450 [TBL] [Abstract][Full Text] [Related]
2. Effects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: comparison with diazepam and interactions with flumazenil. Löscher W; Hönack D Br J Pharmacol; 1994 Dec; 113(4):1349-57. PubMed ID: 7889291 [TBL] [Abstract][Full Text] [Related]
3. Comparative patch clamp studies on the kinetics and selectivity of glutamate receptor antagonism by 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) and 1-(4-amino-phenyl)-4-methyl-7,8-methyl-endioxyl-5H-2,3-benzodiaze pine (GYKI 52466). Parsons CG; Gruner R; Rozental J Neuropharmacology; 1994 May; 33(5):589-604. PubMed ID: 7523977 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and anticonvulsant activity of novel and potent 2,3-benzodiazepine AMPA/kainate receptor antagonists. Grasso S; De Sarro G; De Sarro A; Micale N; Zappalà M; Puia G; Baraldi M; De Micheli C J Med Chem; 1999 Oct; 42(21):4414-21. PubMed ID: 10543885 [TBL] [Abstract][Full Text] [Related]
6. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice. Chapman AG; Smith SE; Meldrum BS Epilepsy Res; 1991 Jul; 9(2):92-6. PubMed ID: 1794356 [TBL] [Abstract][Full Text] [Related]
7. Influence of combined treatment with NMDA and non-NMDA receptor antagonists on electroconvulsions in mice. Czuczwar SJ; Borowicz KK; Kleinrok Z; Tutka P; Zarnowski T; Turski WA Eur J Pharmacol; 1995 Aug; 281(3):327-33. PubMed ID: 8521917 [TBL] [Abstract][Full Text] [Related]
8. A new pyrrolyl-quinoxalinedione series of non-NMDA glutamate receptor antagonists: pharmacological characterization and comparison with NBQX and valproate in the kindling model of epilepsy. Löscher W; Lehmann H; Behl B; Seemann D; Teschendorf HJ; Hofmann HP; Lubisch W; Höger T; Lemaire HG; Gross G Eur J Neurosci; 1999 Jan; 11(1):250-62. PubMed ID: 9987029 [TBL] [Abstract][Full Text] [Related]
9. Comparative anticonvulsant activity of N-acetyl-1-aryl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives in rodents. Ferreri G; Chimirri A; Russo E; Gitto R; Gareri P; De Sarro A; De Sarro G Pharmacol Biochem Behav; 2004 Jan; 77(1):85-94. PubMed ID: 14724045 [TBL] [Abstract][Full Text] [Related]
10. Blocking the trigeminal EPSP in rat abducens motoneurons in vivo with the AMPA antagonists NBQX and GYKI 53655. Ruiz A; Durand J Brain Res Bull; 2000 May; 52(2):99-107. PubMed ID: 10808079 [TBL] [Abstract][Full Text] [Related]
11. Comparative anticonvulsant activity of some 2,3-benzodiazepine derivatives in rodents. De Sarro G; Ferreri G; Gareri P; Russo E; De Sarro A; Gitto R; Chimirri A Pharmacol Biochem Behav; 2003 Feb; 74(3):595-602. PubMed ID: 12543224 [TBL] [Abstract][Full Text] [Related]
14. Differential antagonism of alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid-preferring and kainate-preferring receptors by 2,3-benzodiazepines. Wilding TJ; Huettner JE Mol Pharmacol; 1995 Mar; 47(3):582-7. PubMed ID: 7700255 [TBL] [Abstract][Full Text] [Related]
15. New non competitive AMPA antagonists. Abrahám G; Sólyom S; Csuzdi E; Berzsenyi P; Ling I; Tarnawa I; Hámori T; Pallagi I; Horváth K; Andrási F; Kapus G; Hársing LG; Király I; Patthy M; Horváth G Bioorg Med Chem; 2000 Aug; 8(8):2127-43. PubMed ID: 11003158 [TBL] [Abstract][Full Text] [Related]
16. Interaction of GYKI 52466, a selective non-competitive antagonist of AMPA/kainate receptors, with conventional antiepileptic drugs in amygdala-kindled seizures in rats. Borowicz KK; Duda AM; Kleinrok Z; Czuczwar SJ Pol J Pharmacol; 2001; 53(2):101-8. PubMed ID: 11787948 [TBL] [Abstract][Full Text] [Related]
17. Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant activity. Bigge CF; Malone TC; Boxer PA; Nelson CB; Ortwine DF; Schelkun RM; Retz DM; Lescosky LJ; Borosky SA; Vartanian MG J Med Chem; 1995 Sep; 38(19):3720-40. PubMed ID: 7562904 [TBL] [Abstract][Full Text] [Related]
18. Kainate/AMPA receptor antagonists are anticonvulsant against the tonic hindlimb component of pentylenetetrazol-induced seizures in developing rats. Velísek L; Kubová H; Mares P; Vachová D Pharmacol Biochem Behav; 1995 May; 51(1):153-8. PubMed ID: 7617727 [TBL] [Abstract][Full Text] [Related]
19. Novel potent AMPA/kainate receptor antagonists: synthesis and anticonvulsant activity of a series of 2-[(4-alkylsemicarbazono)-(4-amino-phenyl)methyl]-4,5-methylenedioxyphenylacetic acid alkyl esters. Micale N; Zappalà M; Grasso S; Puja G; De Sarro G; Ferreri G; De Sarro A; Toma L; De Micheli C J Med Chem; 2002 Sep; 45(20):4433-42. PubMed ID: 12238923 [TBL] [Abstract][Full Text] [Related]
20. Some behavioral effects of AMPA/kainate receptor agonist and antagonists. Członkowska A; Siemiatkowski M; Płaźnik A J Physiol Pharmacol; 1997 Sep; 48(3):479-88. PubMed ID: 9376630 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]